Head of Manufacturing Operation, Lonza
Pascal holds a PhD in Cell Biology and an Executive MBA (EPFL/UNIL/Texas University). Being in the Biotech industry for a bit more than 15 years, he moved gradually from R&D and Process Development
towards Biomanufacturing. After his PhD and some entrepreneurial experiences in Drug Discovery and Cell Therapy, he has been working several years for a Swiss CDMO (EPFL spin off) and joined Glenmark Pharmaceuticals SA early 2014 to become Head of Process Development and Manufacturing, leading the development of molecules (monoclonal and bispecific antibodies) and the subsequent clinical in-house production
for Phase I/II. He was also participating in Tech Transfer for late stage/commercial production with large CDMOs.
He joined Merck KGa by the end of 2017 as UpStream Processing Manager (Aubonne, CH) and quickly became Production Associate Director, leading all the UpStream and DownStream Processing activities for commercial products. He managed also a Tech Transfer of a new immune-cytokine molecule from early clinical phases to Phase III. In August 2021, he took a new challenge and moved to Wallis where he joined Lonza as Senior Director, leading the Drug Substance Manufacturing Operations in a new state of the art, multi-product and fully single use facility, part of the massive Ibex program. Pascal is also active as board member and advisors for different start-ups and is a lecturer and GMP module coordinator for EPFL and a French University.